அமல் உபாதியாய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SHARE
Weekly injections of an appetite suppressant combined with a healthy lifestyle helped almost 2,000 overweight adults lose up to a fifth of their bodyweight in a recent trial.
In research funded by Danish pharmaceutical firm Novo Nordisk, a 2.4mg dose of semaglutide was found to encourage significant weight loss in 1,961 people with a body mass index of at least 30.
This is a game-changer in the amount of weight loss it causes
Prof Rachel Batterham, University College London
The double-blind trial, where half the subjects were given a placebo, saw an average change of 15 per cent in bodyweight in those who took the drug, compared with just 2.4 per cent in those who just changed their lifestyle. ....

Abu Dhabi , Rachel Batterham , Amal Upadhyay , Rachel Batterham Profbatterham , University College London , Coronavirus Clinical Characterisation Consortium , Novo Nordisk , University College , New England Medical Journal , United Kingdom Based , Professor Rachel Batterham , Prof Rachel Batterham , Cleveland Clinic Abu Dhabi , United Kingdom , Aster Hospital , Nick Webster , அமல் உபாதியாய் , பல்கலைக்கழகம் கல்லூரி லண்டன் , பல்கலைக்கழகம் கல்லூரி , புதியது இங்கிலாந்து மருத்துவ இதழ் , ஒன்றுபட்டது கிஂக்டம் அடிப்படையிலானது , ஒன்றுபட்டது கிஂக்டம் , அஸ்டெர் மருத்துவமனை , நிக் வெப்ஸ்டர் ,